Please login to the form below

Not currently logged in
Email:
Password:

respiratory syncytial virus

This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

rights to its respiratory syncytial virus (RSV) drugs. ... The deal covers US rights to AZ’s already-marketed antibody Synagis (palivizumab), which is the only approved prophylaxis against the virus – as well as profit sharing for follow-up candidate

Latest news

  • Moderna files record $500m IPO for RNA pipeline Moderna files record $500m IPO for RNA pipeline

    as well as vaccines for viral infections such as respiratory syncytial virus (RSV), influenza, chikungunya and Zika.

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Following after, Ablynx is expecting phase IIb clinical trial results for its respiratory syncytial virus (RSV) therapy ALX-0171 before the end of the year.

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    This is the second pipeline disappointment for Regeneron in recent months after it abandoned respiratory syncytial virus (RSV) candidate suptavumab, which failed to hit the mark in a phase III trial

  • Janssen’s quest to prevent diseases taking hold Janssen’s quest to prevent diseases taking hold

    Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs ... and respiratory tract that affects children and the

  • Regeneron drops RSV drug Regeneron drops RSV drug

    Regeneron has said it will end the development of its late-stage candidate for the prevention of respiratory syncytial virus (RSV) infections after disappointing results in a phase III trial. ... At the moment the only approved prophylaxis against the

More from news
Approximately 2 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

  • Pharma deals during June 2013 Pharma deals during June 2013

    Still in the respiratory space, Teva acquired the privately owned drug delivery company MicroDose Therapeutx for an initial $40m with further payments of up to $125m. ... The deal brings to Teva a multi dose dry powder nebuliser technology and MDT-637, a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics